查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1959944

非酒精性脂肪性肝炎治療市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類型、最終用戶、地區和競爭格局分類，2021-2031年

Non-Alcoholic Steatohepatitis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球非酒精性脂肪性肝炎治療市場預計將大幅成長，從 2025 年的 23.9 億美元成長到 2031 年的 88.4 億美元，複合年成長率為 24.36%。

該市場涉及旨在減輕代謝紊亂引起的肝臟發炎和纖維化的藥物干預措施，其主要促進因素是全球肥胖和第2型糖尿病盛行率的上升，而這些疾病需要臨床治療以預防肝硬化。此外，近期標靶治療的監管核准證實了該領域的商業性可行性，並推動了投資。肝臟基金會估計，到2025年，美國將有900萬至1500萬成年人受到代謝紊亂相關性脂肪性肝炎的影響。

市場概覽
預測期 2027-2031
市場規模：2025年 23.9億美元
市場規模：2031年 88.4億美元
複合年成長率：2026-2031年 24.36%
成長最快的細分市場 維生素E和PIOGLITAZONE部分
最大的市場 北美洲

然而，快速的市場擴張受到診斷複雜性的限制，難以準確識別合格的患者，尤其是目前仍將侵入性肝臟切片檢查作為確診進行性纖維化的黃金標準。這項要求嚴重阻礙了篩檢和治療的廣泛發展，使患者預後複雜化，並限制了診斷率。因此，對侵入性操作的依賴限制了新興治療方法的潛在收入來源，並減緩了新治療方法的整體商業性化。

市場促進因素

推動全球非酒精性脂肪性肝炎 (NAF) 治療市場擴張的主要因素是肥胖和代謝併發症的日益普遍。這是因為代謝功能障礙會導致肝臟脂肪堆積和發炎。體重指數 (BMI) 和肝病同時上升，導致需要藥物治療的患者群體迅速擴大，隨著全球生活方式相關風​​險因素的惡化，對有效治療方法的需求預計將持續成長。世界衛生組織 (WHO) 在《2024 年世界肥胖日》報告中強調了這一緊迫性，該報告指出，截至 2022 年，全球有超過 10 億人肥胖，凸顯了針對肝纖維化代謝根本原因的治療方法的必要性。

同時，強大的後期臨床開發平臺和一系列歷史性的監管核准推動了市場發展，這些都展現了該領域的商業性潛力，加速了從支持性治療到標靶疾病修正治療的轉變。一系列監管核准刺激了進一步的投資；例如，2024年3月，Madrigal Pharmaceuticals宣布其首個核准療法Lezdifra的批發價格定為每年47,400美元，從而建立了一個明確的收入模式。臨床創新也十分活躍，勃林格殷格翰於2024年2月宣布，在II期臨床試驗中，接受sulfodutide治療的患者中高達83%的病情得到了顯著改善。

市場挑戰

全球非酒精性脂肪性肝炎治療市場成長的主要障礙在於診斷過程的複雜性，而這種複雜性又依賴侵入性肝臟切片檢查。這些手術耗費資源且風險較高，阻礙了廣泛的人群篩檢，延誤了纖維化的臨床確診，並在患者識別過程中造成了嚴重的瓶頸。這種對侵入性「黃金標準」的依賴，使得無法及時識別那些明顯需要藥物治療的患者，人為地低估了符合處方治療條件的患者人數，使其與實際疾病患病率不符。

這種持續存在的缺口顯著限制了已通過核准治療方法的獲利能力，因為如果沒有檢驗的患者群體，市場就無法擴張。根據全球河流研究所（Global River Institute）預測，截至2024年，全球約95%的代謝紊亂相關性脂肪性肝炎（MASH）患者仍未被確診。如此低的診斷率直接阻礙了商業性化應用，因為當絕大多數目標族群未被臨床確診時，製藥公司就無法有效地實現治療產品的獲利。

市場趨勢

GLP-1受體促效劑的問世標誌著市場的一個變革性轉折點，將治療重點從以肝臟為中心的標靶治療轉向全身代謝調節。這種方法利用腸泌素類似藥物來解決潛在的代謝因素，例如胰島素阻抗和脂毒性，並在後期臨床試驗中展現出顯著療效，確立了這些藥物作為未來治療模式的基礎。例如，2024年11月，諾和諾德公司報告稱，在其III期ESSENCE試驗中，接受2.4 mgSemaglutide肽治療的成年患者中有62.9%實現了脂肪性肝炎的緩解，且未出現纖維化加重，與安慰劑組的34.1%相比，差異顯著。

同時，非侵入性診斷生物標記的引入正在重塑臨床開發和患者分層，減少了對組織學檢驗的依賴。製藥開發商正在利用影像學和循環標記來加強替代終點的驗證，以簡化受試者招募流程並監測治療檢驗，同時避免與切片檢查相關的操作風險。 Akero Therapeutics公司在2024年11月發布的一項研究結果印證了這一趨勢。研究發現，在接受50毫克依非韋倫治療的患者中，超過40%的患者在包括FibroScan和ELF評分在內的三個獨立指標上顯示出肝纖維化的消退，而安慰劑組的比例為0%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：非酒精性脂肪性肝炎治療的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物類型（維生素E和PIOGLITAZONE、奧貝膽酸（OCA）、雷尼菲拉諾、Semaglutide肽、瑞美替洛、Aramchol、塞尼克利維羅克等）
    • 依最終用戶（醫院藥局、零售藥局/專科藥局、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美非酒精性脂肪性肝炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲非酒精性脂肪性肝炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區非酒精性脂肪性肝炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲非酒精性脂肪性肝炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲非酒精性脂肪性肝炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球非酒精性脂肪性肝炎治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Intercept Pharmaceuticals Inc.
  • Galmed Research & Development Ltd.
  • INVENTIVA SA
  • AbbVie Inc.
  • Galectin Therapeutics Inc.
  • Madrigal Pharmaceuticals Inc.
  • NGM Biopharmaceuticals Inc.
  • Novo Nordisk A/S
  • Bristol Myers Squibb
  • Gilead Sciences Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24045

The Global Non-Alcoholic Steatohepatitis Treatment Market is projected to experience substantial growth, expanding from USD 2.39 Billion in 2025 to USD 8.84 Billion by 2031 at a CAGR of 24.36%. This market involves pharmaceutical interventions aimed at mitigating liver inflammation and fibrosis caused by metabolic dysfunction, driven largely by the rising global prevalence of obesity and type 2 diabetes which necessitates clinical management to prevent cirrhosis. Furthermore, the sector's commercial viability has been confirmed by recent regulatory approvals of targeted therapeutics, stimulating investment; the American Liver Foundation estimated that metabolic dysfunction-associated steatohepatitis would affect between nine and 15 million adults in the United States in 2025.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.39 Billion
Market Size 2031USD 8.84 Billion
CAGR 2026-203124.36%
Fastest Growing SegmentVitamin E And Pioglitazone Segment
Largest MarketNorth America

However, rapid market expansion is hindered by the diagnostic complexity involved in accurately identifying eligible patients, specifically the continued reliance on invasive liver biopsies as the gold standard for confirming advanced fibrosis. This requirement creates a significant barrier to widespread screening and treatment adoption, complicating the patient journey and limiting diagnosis rates. Consequently, the dependence on invasive procedures restricts the accessible revenue base for emerging therapies and slows the overall commercial uptake of new treatments.

Market Driver

The primary catalyst expanding the Global Non-Alcoholic Steatohepatitis Treatment Market is the escalating prevalence of obesity and metabolic comorbidities, as metabolic dysfunction leads to liver fat accumulation and inflammation. The synchronization between rising body mass index and liver disease creates a rapidly growing patient pool that requires pharmacological intervention, ensuring sustained demand for effective therapeutics as lifestyle-related risk factors intensify globally. This urgency is highlighted by the World Health Organization's 'World Obesity Day 2024' release, which noted that over one billion people worldwide were living with obesity in 2022, underscoring the need for treatments targeting the metabolic roots of liver fibrosis.

Simultaneously, the market is propelled by a robust late-stage clinical pipeline and historic regulatory approvals that have validated the sector's commercial potential, accelerating the transition from supportive care to targeted disease-modifying therapies. Successful regulatory outcomes have encouraged further investment; for instance, Madrigal Pharmaceuticals reported in March 2024 that the wholesale acquisition cost for Rezdiffra, the first approved treatment, was set at USD 47,400 annually, establishing a tangible revenue model. Clinical innovation remains active, as evidenced by Boehringer Ingelheim's February 2024 statement that up to 83 percent of patients treated with survodutide achieved significant disease improvement in Phase II trials.

Market Challenge

A substantial obstacle to the growth of the Global Non-Alcoholic Steatohepatitis Treatment Market is the diagnostic complexity associated with the reliance on invasive liver biopsies. Because these procedures are resource-intensive and carry risks, they deter widespread population screening and delay the clinical confirmation of fibrosis, creating a severe bottleneck in the patient identification process. This reliance on an invasive gold standard prevents the timely categorization of individuals who explicitly require pharmaceutical intervention, keeping the volume of patients eligible for prescription therapies artificially low relative to actual disease prevalence.

This persistent gap significantly restricts the revenue potential for approved treatments, as the market cannot expand without a validated patient base. According to the Global Liver Institute, approximately 95 percent of individuals affected by metabolic dysfunction-associated steatohepatitis remained undiagnosed globally in 2024. This extremely low diagnosis rate directly hampers commercial uptake, as pharmaceutical companies are unable to effectively monetize their therapeutic products when the vast majority of the target demographic has not been clinically identified to receive treatment.

Market Trends

The integration of GLP-1 receptor agonists represents a transformative shift in the market, moving the therapeutic focus from exclusively liver-centric targets to systemic metabolic regulation. By leveraging incretin mimetics to address underlying metabolic drivers such as insulin resistance and lipotoxicity, this approach has demonstrated robust efficacy in late-stage clinical evaluations, establishing these agents as cornerstones of future treatment paradigms. For example, Novo Nordisk reported in November 2024 that 62.9 percent of adults treated with semaglutide 2.4 mg in the Phase 3 ESSENCE trial achieved resolution of steatohepatitis without worsening fibrosis, compared to only 34.1 percent of those receiving a placebo.

Simultaneously, the adoption of non-invasive diagnostic biomarkers is reshaping clinical development and patient stratification by reducing reliance on histological verification. Pharmaceutical developers are increasingly validating surrogate endpoints using imaging and circulating markers to streamline trial recruitment and monitor therapeutic response without the procedural risks of biopsies. This trend is illustrated by Akero Therapeutics' November 2024 announcement, which stated that over 40 percent of participants treated with efruxifermin 50mg showed regression of liver fibrosis across three orthogonal measures, including FibroScan and the ELF score, compared to zero percent for the placebo group.

Key Market Players

  • Intercept Pharmaceuticals Inc.
  • Galmed Research & Development Ltd.
  • INVENTIVA S.A.
  • AbbVie Inc.
  • Galectin Therapeutics Inc.
  • Madrigal Pharmaceuticals Inc.
  • NGM Biopharmaceuticals Inc.
  • Novo Nordisk A/S
  • Bristol Myers Squibb
  • Gilead Sciences Inc.

Report Scope

In this report, the Global Non-Alcoholic Steatohepatitis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Alcoholic Steatohepatitis Treatment Market, By Drug Type

  • Vitamin E and Pioglitazone
  • Obeticholic Acid (OCA)
  • Lanifibranor
  • Semaglutide
  • Resmetirom
  • Aramchol
  • Cenicriviroc
  • Others

Non-Alcoholic Steatohepatitis Treatment Market, By End-User

  • Hospital Pharmacies
  • Retail and Specialty Pharmacies
  • Others

Non-Alcoholic Steatohepatitis Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Alcoholic Steatohepatitis Treatment Market.

Available Customizations:

Global Non-Alcoholic Steatohepatitis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Alcoholic Steatohepatitis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Vitamin E and Pioglitazone, Obeticholic Acid (OCA), Lanifibranor, Semaglutide, Resmetirom, Aramchol, Cenicriviroc, Others)
    • 5.2.2. By End-User (Hospital Pharmacies, Retail and Specialty Pharmacies, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Non-Alcoholic Steatohepatitis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By End-User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By End-User
    • 6.3.2. Canada Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By End-User
    • 6.3.3. Mexico Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By End-User

7. Europe Non-Alcoholic Steatohepatitis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By End-User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By End-User
    • 7.3.2. France Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By End-User
    • 7.3.3. United Kingdom Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By End-User
    • 7.3.4. Italy Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By End-User
    • 7.3.5. Spain Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By End-User

8. Asia Pacific Non-Alcoholic Steatohepatitis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By End-User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By End-User
    • 8.3.2. India Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By End-User
    • 8.3.3. Japan Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By End-User
    • 8.3.4. South Korea Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By End-User
    • 8.3.5. Australia Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By End-User

9. Middle East & Africa Non-Alcoholic Steatohepatitis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By End-User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By End-User
    • 9.3.2. UAE Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By End-User
    • 9.3.3. South Africa Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By End-User

10. South America Non-Alcoholic Steatohepatitis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By End-User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By End-User
    • 10.3.2. Colombia Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By End-User
    • 10.3.3. Argentina Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Non-Alcoholic Steatohepatitis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Intercept Pharmaceuticals Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Galmed Research & Development Ltd.
  • 15.3. INVENTIVA S.A.
  • 15.4. AbbVie Inc.
  • 15.5. Galectin Therapeutics Inc.
  • 15.6. Madrigal Pharmaceuticals Inc.
  • 15.7. NGM Biopharmaceuticals Inc.
  • 15.8. Novo Nordisk A/S
  • 15.9. Bristol Myers Squibb
  • 15.10. Gilead Sciences Inc.

16. Strategic Recommendations

17. About Us & Disclaimer